Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- a population-based study

Authors: Jiaofeng Huang, Haoyang Zhang, Shiying Liu, Mingfang Wang, Bo Wan, Bharat Velani, Yueyong Zhu, Su Lin

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Previous studies have suggested that Toxoplasma gondii (T. gondii) infection might be associated with fatty liver disease. However, the relationship between non-alcoholic fatty liver disease (NAFLD) and T. gondii infection has not been investigated in a large population. We aimed to study the relationship between those two diseases using a population-based dataset from the United States.

Methods

The data were collected from the third National Health and Nutrition Examination Survey (NHANES III) between 1988 and 1994. Statistical analysis was applied to compare the prevalence of NAFLD in anti-T. gondii antibody-positive participants with antibody-negative ones.

Results

A total of 9465 persons with a mean age of 44.33 ± 16.21 years, 46.9% of which were males, were included in the final analysis. Their mean BMI was 27.60 ± 5.96 kg/m2. A total of 2520 participants (26.62%) were positive for the T. gondii antibody. There was an increasing trend of seroprevalence of T. gondii with age (P for trend < 0.001). The incidence of NAFLD in the seropositive group was higher than that in the seronegative group (27.10% vs 23.40%, p < 0.001). In addition to this, metabolic biomarkers, including serum lipid, fasting blood-glucose, and uric acid were also significantly higher in the seropositive group. However, multivariate analysis revealed that T. gondii infection was not an independent risk factor for NAFLD. Age was independently correlated with both the prevalence of T. gondii and NAFLD.

Conclusions

Patients with T. gondii infection may have a higher prevalence of NAFLD. Age may have an effect on the increase of NAFLD in the T. gondii seropositive population.
Literature
2.
go back to reference Chorlton S. Toxoplasma gondii and schizophrenia: a review of published RCTs. Parasitol Res. 2017;116(7):1793–9.CrossRef Chorlton S. Toxoplasma gondii and schizophrenia: a review of published RCTs. Parasitol Res. 2017;116(7):1793–9.CrossRef
3.
go back to reference Ansarilari M, Farashbandi H, Mohammadi F. Association of Toxoplasma gondii infection with schizophrenia and its relationship with suicide attempts in these patients.Tropical Med Int Health. 2017;22(10):1322–27. Ansarilari M, Farashbandi H, Mohammadi F. Association of Toxoplasma gondii infection with schizophrenia and its relationship with suicide attempts in these patients.Tropical Med Int Health. 2017;22(10):1322–27.
4.
go back to reference Abd El-Rehim El-Henawy A, Abdel-Razik A, Zakaria S, Elhammady D, Saudy N, Azab MS. Is toxoplasmosis a potential risk factor for liver cirrhosis? Asian Pac J Trop Med. 2015;8(10):784–91.CrossRefPubMed Abd El-Rehim El-Henawy A, Abdel-Razik A, Zakaria S, Elhammady D, Saudy N, Azab MS. Is toxoplasmosis a potential risk factor for liver cirrhosis? Asian Pac J Trop Med. 2015;8(10):784–91.CrossRefPubMed
5.
go back to reference Da Silva AS, Tonin AA, Thorstenberg ML, Leal DB, Fighera R, Flores MM, et al. Relationship between butyrylcholinesterase activity and liver injury in mice acute infected with Toxoplasma gondii. Pathol Res Pract. 2013;209(2):95–8.CrossRefPubMed Da Silva AS, Tonin AA, Thorstenberg ML, Leal DB, Fighera R, Flores MM, et al. Relationship between butyrylcholinesterase activity and liver injury in mice acute infected with Toxoplasma gondii. Pathol Res Pract. 2013;209(2):95–8.CrossRefPubMed
6.
go back to reference El-Nahas HA, El-Tantawy NL, Farag RE, Alsalem AM. Toxoplasma gondii infection among chronic hepatitis C patients: a case-control study. Asian Pac J Trop Med. 2014;7(8):589–93.CrossRefPubMed El-Nahas HA, El-Tantawy NL, Farag RE, Alsalem AM. Toxoplasma gondii infection among chronic hepatitis C patients: a case-control study. Asian Pac J Trop Med. 2014;7(8):589–93.CrossRefPubMed
7.
go back to reference Tian AL, Li GX, Elsheikha HM, Gardner DS, Zhang XY, Dong W, et al. Seroepidemiology of Toxoplasma gondii infection in patients with liver disease in eastern China. Epidemiol Infect. 2017;145(11):2296–302.CrossRefPubMed Tian AL, Li GX, Elsheikha HM, Gardner DS, Zhang XY, Dong W, et al. Seroepidemiology of Toxoplasma gondii infection in patients with liver disease in eastern China. Epidemiol Infect. 2017;145(11):2296–302.CrossRefPubMed
8.
go back to reference El-Sayed NM, Ramadan ME, Ramadan ME. Toxoplasma gondii infection and chronic liver diseases: evidence of an association. Trop Med Infect Dis. 2016;1(1):7.CrossRefPubMedCentral El-Sayed NM, Ramadan ME, Ramadan ME. Toxoplasma gondii infection and chronic liver diseases: evidence of an association. Trop Med Infect Dis. 2016;1(1):7.CrossRefPubMedCentral
9.
go back to reference Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.CrossRefPubMed
10.
go back to reference He JJ, Ma J, Elsheikha HM, Song HQ, Huang SY, Zhu XQ. Transcriptomic analysis of mouse liver reveals a potential hepato-enteric pathogenic mechanism in acute Toxoplasma gondii infection. Parasit Vectors. 2016;9(1):427.CrossRefPubMedPubMedCentral He JJ, Ma J, Elsheikha HM, Song HQ, Huang SY, Zhu XQ. Transcriptomic analysis of mouse liver reveals a potential hepato-enteric pathogenic mechanism in acute Toxoplasma gondii infection. Parasit Vectors. 2016;9(1):427.CrossRefPubMedPubMedCentral
13.
go back to reference Howell CR, Fontaine K, Ejima K, Ness KK, Cherrington A, Mehta T. Maximum Lifetime Body Mass Index and Mortality in Mexican American Adults: the National Health and Nutrition Examination Survey III (1988–1994) and NHANES 1999–2010. Prev Chronic Dis. 2017;14:E67.CrossRefPubMedPubMedCentral Howell CR, Fontaine K, Ejima K, Ness KK, Cherrington A, Mehta T. Maximum Lifetime Body Mass Index and Mortality in Mexican American Adults: the National Health and Nutrition Examination Survey III (1988–1994) and NHANES 1999–2010. Prev Chronic Dis. 2017;14:E67.CrossRefPubMedPubMedCentral
18.
go back to reference Jones JL, Kruszon-Moran D, Rivera HN, Price C, Wilkins PP. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135–9.CrossRefPubMedPubMedCentral Jones JL, Kruszon-Moran D, Rivera HN, Price C, Wilkins PP. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135–9.CrossRefPubMedPubMedCentral
19.
go back to reference Jones JL, Kruszon-Moran D, Elder S, Rivera HN, Press C, Montoya JG, et al. Toxoplasma gondii infection in the United States, 2011-2014. Am J Trop Med Hyg. 2018;98(2):551–7.CrossRefPubMed Jones JL, Kruszon-Moran D, Elder S, Rivera HN, Press C, Montoya JG, et al. Toxoplasma gondii infection in the United States, 2011-2014. Am J Trop Med Hyg. 2018;98(2):551–7.CrossRefPubMed
20.
go back to reference Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, et al. Non-alcoholic fatty liver disease: a sign of systemic disease. Metabolism. 2017;72:94–108.CrossRefPubMed Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, et al. Non-alcoholic fatty liver disease: a sign of systemic disease. Metabolism. 2017;72:94–108.CrossRefPubMed
21.
go back to reference Augustin S, Graupera I, Caballeria J. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc). 2017;149(12):542–49. Augustin S, Graupera I, Caballeria J. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc). 2017;149(12):542–49.
22.
go back to reference Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75(16):2951–61.CrossRefPubMed Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75(16):2951–61.CrossRefPubMed
23.
go back to reference Nassief Beshay EV, El-Refai SA, Helwa MA, Atia AF, Dawoud MM. Toxoplasma gondii as a possible causative pathogen of type-1 diabetes mellitus: evidence from case-control and experimental studies. Exp Parasitol. 2018;188:93–101.CrossRefPubMed Nassief Beshay EV, El-Refai SA, Helwa MA, Atia AF, Dawoud MM. Toxoplasma gondii as a possible causative pathogen of type-1 diabetes mellitus: evidence from case-control and experimental studies. Exp Parasitol. 2018;188:93–101.CrossRefPubMed
24.
go back to reference Han Y, Nie L, Ye X, Zhou Z, Huang S, Zeng C, et al. The association between Toxoplasma gondii infection and hypertensive disorders in T2DM patients: a case-control study in the Han Chinese population. Parasitol Res. 2018;117(3):689–95.CrossRefPubMed Han Y, Nie L, Ye X, Zhou Z, Huang S, Zeng C, et al. The association between Toxoplasma gondii infection and hypertensive disorders in T2DM patients: a case-control study in the Han Chinese population. Parasitol Res. 2018;117(3):689–95.CrossRefPubMed
25.
go back to reference Majidiani H, Dalvand S, Daryani A, Galvan-Ramirez ML, Foroutan-Rad M. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Braz J Infect Dis. 2016;20(6):605–9.CrossRefPubMed Majidiani H, Dalvand S, Daryani A, Galvan-Ramirez ML, Foroutan-Rad M. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Braz J Infect Dis. 2016;20(6):605–9.CrossRefPubMed
26.
go back to reference Alvarado-Esquivel C, Maldonado-Soto E, Sanchez-Anguiano LF, Hernandez-Tinoco J, Ramos-Nevarez A, Cerrillo-Soto SM, et al. Lack of serological and molecular association between Toxoplasma gondii exposure and obesity: a case-control study. Int J Biomed Sci. 2017;13(2):74–8.PubMedPubMedCentral Alvarado-Esquivel C, Maldonado-Soto E, Sanchez-Anguiano LF, Hernandez-Tinoco J, Ramos-Nevarez A, Cerrillo-Soto SM, et al. Lack of serological and molecular association between Toxoplasma gondii exposure and obesity: a case-control study. Int J Biomed Sci. 2017;13(2):74–8.PubMedPubMedCentral
27.
go back to reference Reeves GM, Mazaheri S, Snitker S, Langenberg P, Giegling I, Hartmann AM, et al. A positive association between T. gondii seropositivity and obesity. Front Public Health. 2013;1:73.CrossRefPubMedPubMedCentral Reeves GM, Mazaheri S, Snitker S, Langenberg P, Giegling I, Hartmann AM, et al. A positive association between T. gondii seropositivity and obesity. Front Public Health. 2013;1:73.CrossRefPubMedPubMedCentral
28.
go back to reference Alvarado-Esquivel C, Torres-Berumen JL, Estrada-Martinez S, Liesenfeld O, Mercado-Suarez MF. Toxoplasma gondii infection and liver disease: a case-control study in a northern Mexican population. Parasit Vectors. 2011;4:75.CrossRefPubMedPubMedCentral Alvarado-Esquivel C, Torres-Berumen JL, Estrada-Martinez S, Liesenfeld O, Mercado-Suarez MF. Toxoplasma gondii infection and liver disease: a case-control study in a northern Mexican population. Parasit Vectors. 2011;4:75.CrossRefPubMedPubMedCentral
Metadata
Title
Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- a population-based study
Authors
Jiaofeng Huang
Haoyang Zhang
Shiying Liu
Mingfang Wang
Bo Wan
Bharat Velani
Yueyong Zhu
Su Lin
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3547-1

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.